Balyasny Asset Management
EDIT icon

Balyasny Asset Management’s Editas Medicine EDIT Stock Holding History

Balyasny Asset Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-97,500
Closed -$3.49M – 1749
2018
Q2 		$3.49M Buy
+97,500
New +$3.45M 0.02% 767

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Balyasny Asset Management's EDIT Position: Q1 2025 in Review

Balyasny Asset Management sold out of Editas Medicine (EDIT) in Q1 2025, closing a stake of 1,300,604 shares — an estimated $1.65M sold.

Balyasny Asset Management first reported a position in EDIT in Q3 2016 and held it in 16 quarters. The position peaked at $3.72M in Q2 2022. 194 funds tracked by Wall St. Rank hold EDIT as of Q1 2025.

  • Balyasny Asset Management reported no remaining Editas Medicine position as of Q1 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 1,300,604 Editas Medicine shares in Q1 2025, an estimated $1.65M.
  • Balyasny Asset Management first reported a position in Editas Medicine in Q3 2016 and held it in 16 quarters.
  • Balyasny Asset Management's Editas Medicine position peaked at $3.72M in Q2 2022.
  • 194 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2025.

Based on Balyasny Asset Management's 13F filing for Q1 2025, filed 15 May 2025.